and symptoms are typically breathing-related (e.g. chronic cough, exertional dyspnea, expectoration, and wheeze) . It is believed that a once daily ^-adrenoceptor agonist would be of tremendous value in the treatment of these conditions, with the added benefit of increased convenience for the patient population.
There has been considerable interest in the discovery of a once daily |b2-adrenoceptor agonist with a recent flurry of presentations, patent applications, and licensing agreements from a number of institutions. The aim of this review is to update the current state of the field, including clinical data for agents where available. The review is structured according to the various ^-adrenoceptor agonist head groups employed by researchers and concludes with a discussion regarding the potential development of dual pharmacology agents.
Was this article helpful?